dr rosenberg research medical center

Dr. William S. Rosenberg MD

Neurosurgery

Research Medical Center , +1 other

Patients Top Choice

Patient Rating

100 Reviews

21 + Years of Experience

Patient Awards

in 3 condition s

Research Medical Center

2330 East Meyer Boulevard , Kansas City , MO

Doctor's Details

Specialties

Subspecialties

Neurosurgical Spine Surgery

Patient experience.

Provides clear explanation

Makes time for patients

Patients' top choice award

Provides clear information and answers questions in a way patients understand.

Spends appropriate amount of time with patient and provides thorough examinations.

Doctor has top marks across all patient-rated categories

Overall Patient Experience

100 Reviews Total | 62 Reviews Within Last 12 Months

Thoroughness of Examination

Previous patients' satisfaction in their perception of the thoroughness of the examination they received from this physician

Ability to Answer Questions

Previous patients' assessment of this physician's ability to answer all of their questions

Clarity of Instructions

Previous patients' satisfaction in the clarity of this physician's instructions for taking care of their health condition

Provider's follow-up

Previous patients' satisfaction of the followup care they received from this physician and responsiveness to their concerns

Very Positive

Amount of Time with Patient

Previous patients' satisfaction with the time this physician spent with them during appointments

Provider's Attitude

Previous patients' assessment of this physician's friendliness and caring attitude

Perceived Outcomes

Previous patients' satisfaction with the physician's treatment of a condition or outcome of a procedure

Patient Loyalty

Previous patients' trust in this physician, likelihood to see this physician again, or willingness to recommend this physician to another patient

General Feedback

Previous patients' general assessment of this physician

See All Categories

Areas of expertise for dr. rosenberg.

This doctor provides the following types of care. The more often a doctor has treated a particular condition or has performed a particular surgery, the more expertise they may have in treating patients with similar needs. Based on three years (2020-2022) of Medicare data, each scale below indicates the volume of episodes compared to other doctors who treat the same condition. Click here to learn more about our methodology.

Spinal fusion Spinal fusion surgery involves joining two or more vertebrae to treat spine problems and stabilize the spine.

Back and neck pain treatment without fusion Treatment for back and neck pain without fusion can include various surgical approaches.

Craniotomy Craniotomy is a surgical procedure to open the skull, often performed to treat brain conditions.

Looking for something else?

Check to See if Dr. William S. Rosenberg Accepts Your Insurance

Accepts Medicare

Accepts Medicaid

Please contact your provider to confirm if they accept your insurance.

Insurance Carrier

Aetna, Cigna, etc.

Accepted Insurance Plans

Blue Cross and Blue Shield of Kansas City

Blue Cross Blue Shield of Massachusetts

Blue Cross Blue Shield of Michigan

CMS Medicare

Regence Health Plans

United Healthcare

Don`t see your plan listed? Click here to find providers that accept your insurance .

Neurosurgeons Like Dr. Rosenberg Near Me

Samuel Taylon MD

Kansas City , MO

Carlos Bagley MD

Robert Tenny MD

Justin Davis MD

Kansas City , KS

Location & Contact Information

Doctor Address

2330 East Meyer Boulevard, Suite 411, Kansas City, MO, 64132

Affiliated Hospitals

Overland Park Regional Medical Center

Where does Dr. Rosenberg practice?

Doctor’s Office

Research Neuroscience Institute, Llc

Here are other providers that practice at the same doctor's office:

Matt Pierson

Frances Hardaway

Charles Harvey

Robert Singer

Peter Basta

Jayson Neil

Ellen Carpenter

Adult Care Nurse Practitioner

Norman Bamber

John Clough

William Rosenberg

Laura Textor

Nurse Practitioner

Jonathan Chilton

Samuel Taylon

Wendy Spangler

Jill Weller

Tania Pittel

Family Nurse Practitioner

Jessica Uffmann

Sarah Fernholz

Sara Miller

Brian Hutchinson

Acute Care Nurse Practitioner

Hospital Affiliations

Research medical center kansas city, mo.

High Performing in Stroke

Overland Park Regional Medical Center Overland Park, KS

High Performing in Back Surgery (Spinal Fusion)

Education & Experience

Medical school & residency.

Massachusetts General Hospital

Residency , Neurological Surgery , 1988 - 1993

Internship , Surgery , 1987 - 1988

Harvard Medical School

Medical School

Chief Residency , Neurological Surgery , 1993 - 1993

Certifications & Licensure

American Board of Neurological Surgery

Certified in Neurological Surgery

MO State Medical License

Active through 2025

CA State Medical License

Active through

KS State Medical License

Active through 2024

OH State Medical License

Active through 1998

Awards, Honors & Recognitions

AANS Fellow , 2011

CMS Stage 1 2012

Publications

Recalibrating the Glasgow Coma Score as an Age-Adjusted Risk Metric for Neurosurgical Intervention.

Kristin Salottolo, Ripul Panchal, Laxmi Dhakal, Robert Madayag, Kaysie L. Banton, Allen Tanner, William S Rosenberg, David Bar-Or

The American Society of Pain and Neuroscience (ASPN) Best Practices and Guidelines for the Interventional Management of Cancer-Associated Pain.

Mansoor M. Aman, Ammar Mahmoud, Timothy R. Deer, Dawood Sayed, Jonathan M Hagedorn, Shane E. Brogan, Vinita Singh, Amitabh Gulati, Natalie Strand, Jacqueline Weisbein, Johnathan H. Goree, Fangfang Xing, Ali Valimahomed, Daniel J. Pak, Antonios El Helou, Priyanka Ghosh, Krishna B. Shah, Vishal Patel, Alexander Escobar, Keith Schmidt, Jay M Shah, Vishal Varshney, William S. Rosenberg, Sanjeet Narang

Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline on Neuroablative Procedures for Patients With Cancer Pain.

Ahmed M. Raslan, Sharona Ben-Haim, Steven M. Falowski, Andre G. Machado, Jonathan P. Miller, Julie G. Pilitsis, William S. Rosenberg, Joshua M. Rosenow, Jennifer A. Sweet, Ashwin Viswanathan, Christopher J. Winfree, Jason M. Schwalb

Incorporating age improves the Glasgow Coma Scale score for predicting mortality from traumatic brain injury.

Kristin Salottolo, Ripul Panchal, Robert Madayag, Laxmi Dhakal, William Rosenberg, Kaysie L. Banton, David Hamilton, David Bar-Or

Neurosurgical Treatments for Cancer Pain.

Sharona Ben-Haim, Zaman Mirzadeh, William S. Rosenberg

Neurosurgical Management of Cancer Facial Pain.

Zaman Mirzadeh, John P. Sheehy, Sharona Ben-Haim, William S. Rosenberg

Deep Brain Stimulation for Intractable Neuropathic Facial Pain

The Polyanalgesic Consensus Conference (PACC): Recommendations on Intrathecal Drug Infusion Systems Best Practices and Guidelines

Timothy R. Deer, Jason E. Pope, Salim M. Hayek, Anjum Bux, Eric Buchser, Sam Eldabe, Jose De Andres, Michael A. Erdek, Dennis Patin, Jay S. Grider, Daniel M. Doleys, Marilyn S. Jacobs, Tony L. Yaksh, Lawrence Poree, Mark S. Wallace, Joshua P. Prager, Richard Rauck, Oscar DeLeon, Sudhir Diwan, Steven M. Falowski, Helena M. Gazelka, Philip Kim, Michael S. Leong, Robert M. Levy, Gladstone C. McDowell, Porter McRoberts, Ramana K. Naidu, Samir Narouze, Christophe Perruchoud, Steven M. Rosen, William S. Rosenberg, Michael Saulino, Peter S. Staats, Lisa Stearns, Dean Willis, Elliot S. Krames, Marc A. Huntoon, Nagy Mekhail

Percutaneous transoral clivoplasty and upper cervical vertebroplasties for multifocal skeletal lymphangiomatosis resulting in complete resolution of pain: case report.

Christina Huang Wright, Dorian Kusyk, William S. Rosenberg, Jennifer A. Sweet

Letter: A Survey of Chronic Pain Due to Spinal Dural Arteriovenous Fistulae.

William S. Rosenberg

Peripheral nerve stimulation for pain in extremities: An update

Jason E. Pope, Jonathan D. Carlson, William S. Rosenberg, Konstantin V. Slavin, Timothy R. Deer

Treatment of medically refractory cancer pain with a combination of intrathecal neuromodulation and neurosurgical ablation: case series and literature review.

J. Nicole Bentley, Ashwin Viswanathan, William S. Rosenberg, Parag G. Patil

Accuracy over space and time of computer-assisted fluoroscopic navigation in the lumbar spine in vivo.

Alfredo Quiñones-Hinojosa, E. Robert Kolen, Peter Jun, William S. Rosenberg, Philip Weinstein

Frameless stereotactic image-guided C1-C2 transarticular screw fixation for atlantoaxial instability: review of 20 patients.

Frank L. Acosta, Alfredo Quinones-Hinojosa, Chirag A. Gadkary, Meic H. Schmidt, Cynthia Chin, Christopher P. Ames, William S. Rosenberg, Philip Weinstein

Titanium cage-assisted polymethylmethacrylate reconstruction for cervical spinal metastasis: technical note.

James K. Liu, William S. Rosenberg, Meic H. Schmidt

General principles in the medical and surgical management of spinal infections: a multidisciplinary approach.

Alfredo Quiñones-Hinojosa, Peter Jun, Richard Jacobs, William S. Rosenberg, Philip Weinstein

Similarity in the fatigue behavior of trabecular bone across site and species.

Sean M. Haddock, Oscar C. Yeh, Praveen V. Mummaneni, William S. Rosenberg, Tony M. Keaveny

Split spinal cord malformation in an elderly patient: case report.

Alfredo Quiñones-Hinojosa, Chirag A Gadkary, Praveen V. Mummaneni, William S. Rosenberg

Quantitative computed tomography-based finite element models of the human lumbar vertebral body: Effect of element size on stiffness, damage, and fracture strength predictions

R. Paul Crawford, William S. Rosenberg, Tony M. Keaveny

Extensive intradural arachnoid cyst of the lumbar spinal canal: Case report

Alfredo Quinones-Hinojosa, Nader Sanai, Nancy J. Fischbein, William S. Rosenberg

Finite element modeling of the human thoracolumbar spine.

Michael A. K. Liebschner, David L. Kopperdahl, William S. Rosenberg, Tony M. Keaveny

Load transfer mechanisms in cylindrical interbody cage constructs.

William J. Palm, William S. Rosenberg, Tony M. Keaveny

C-tau biomarker of neuronal damage in severe brain injured patients: association with elevated intracranial pressure and clinical outcome.

Frank P. Zemlan, Edward C. Jauch, J. Jeffery Mulchahey, S.Prasad Gabbita, William S. Rosenberg, Samuel G Speciale, Mario Zuccarello

Cervical myelopathy associated with degenerative spine disease and ossification of the posterior longitudinal ligament

Meic H. Schmidt, Alfredo Quinones-Hinojosa, William S. Rosenberg

Biomechanical evaluation of a double-threaded pedicle screw in elderly vertebrae.

Praveen V. Mummaneni, Sean M. Haddock, Michael A. K. Liebschner, Tony M. Keaveny, William S. Rosenberg

Effects of bone cement volume and distribution on vertebral stiffness after vertebroplasty.

Michael A. K. Liebschner, William S. Rosenberg, Tony M. Keaveny

Transforaminal lumbar interbody fusion: technique, complications, and early results.

William S. Rosenberg, Praveen V. Mummaneni

Spinal chondrosarcoma following adenocarcinoma of the breast: case report.

Praveen V. Mummaneni, William S. Rosenberg

Quantification of axonal damage in traumatic brain injury: affinity purification and characterization of cerebrospinal fluid tau proteins.

Frank P. Zemlan, William S. Rosenberg, Patricia A. Luebbe, Thomas A. Campbell, Gary E. Dean, Ned E. Weiner, Jeffery A. Cohen, Richard A. Rudick, Daniel Woo

Compression of the upper cervical spinal cord causing symptoms of brainstem compromise. A case report.

William S. Rosenberg, Khalil S. Salame, Kevin V. Shumrick, John M. Tew

Local protective effects of nerve growth factor-secreting fibroblasts against excitotoxic lesions in the rat striatum

David M. Frim, M. Priscilla Short, William S. Rosenberg, Joseph R. Simpson, Xandra O. Breakefield, Ole Isacson

Authentic and artifactual detection of the E. coli lacZ gene product in the rat brain by histochemical methods

William S. Rosenberg, Xandra O. Breakefield, Carlo DeAntonio, Ole Isacson

Cervical disc herniation presenting as a mass lesion posterior to the odontoid process: Report of two cases

William S. Rosenberg, Andrew E. Rosenberg, Charles E. Poletti

Contralateral trigeminal dysaesthesias associated with second cervical nerve compression: a case report

William S. Rosenberg, Brooke Swearingen, Charles E. Poletti

Frequently Asked Questions About Dr. Rosenberg

Can i make an appointment online with dr. rosenberg , does dr. rosenberg offer telehealth, what do patients say about dr. rosenberg , dr. rosenberg accepts insurance, where is dr. rosenberg's office located, what are dr. rosenberg's areas of care.

Let us know if this information is out of date or incorrect.

Are you Dr. William S. Rosenberg ?

Living Well With

Best Immunity Boosters

Exercises to Lower Cholesterol

8 Incredibly Heart-Healthy Foods

health disclaimer »

Disclaimer and a note about your health », you may also like, breastfeeding tips.

Vanessa Caceres March 22, 2024

Does Medicare Cover Home Health Care?

Paul Wynn March 21, 2024

Coming Soon: Best Senior Living Ratings

Ben Harder , Zach Adams and Joshua H. Sandefur March 18, 2024

Best Medicare Advantage Insurance 2024

U.S. News Staff March 15, 2024

How to Shop for Medicare Advantage

Lisa Zamosky and Elaine K. Howley March 15, 2024

Does Medicare Cover Stair Lifts?

Paul Wynn March 14, 2024

What to Pack in Your Hospital Bag

Ruben Castaneda and Christine Comizio March 14, 2024

Coming Soon: Ambulatory Surgery Centers

Ben Harder , Joshua H. Sandefur and Zach Adams March 14, 2024

How to Get Pregnant Fast

Karin Vandraiss March 14, 2024

Medical Costs to Expect in Retirement

Joanne Kaldy and Elaine K. Howley March 13, 2024

William S. Rosenberg , MD FAANS

Neurosurgeon

AREAS OF SPECIALTY

• Complex spinal surgery – degenerative disease, tumors, instrumentation and reconstruction
• Surgical treatment of pain, including chronic, neuropathic and cancer-related symptoms
• Minimally-invasive spinal surgery
• Deep brain stimulation for pain (Obsessive Compulsive Disease)
• Neurosurgical treatment (cingulotomy) for psychiatric disorders (depression, obsessive compulsive disorder)

Dr. William S. Rosenberg attended Harvard Medical School in Boston, Massachusetts, graduating in 1987.  He completed his neurosurgical residency at Massachusetts General Hospital, also in Boston, in 1993. He is a Fellow of the American Association of Neurological Surgery and a Diplomate of the American Board of Neurological Surgery. He is currently President of the AANS/CNS Joint Section on Pain and the Past President and Founder of the Cancer Pain Research Consortium. Dr. Rosenberg serves on the Board of Directors for the American Association of Neurological Surgeons.

Dr. Rosenberg began his career with the Mayfield Clinic in Cincinnati, Ohio (1994-1998), where he was the Director of Neurotrauma and Neurocritical Care at the University of Cincinnati and specialized in complex spinal surgery. He was then recruited to co-direct the Neurospinal Disorders Program in the Department of Neurosurgery at the University of California – San Francisco from 1998 to 2002, where he co-founded the Spinal Biomechanics laboratory at the University of California, Berkeley. Dr. Rosenberg left academic neurosurgery in 2002, joining Midwest Neurosurgery Associates, out of a desire for greater focus on patient care and the ability to spend more time with family.

In Kansas City, Dr. Rosenberg continued to pursue interests in complex spinal surgery. In addition, he expanded his area of expertise to include the treatment of chronic and cancer-related pain. He brought Cyberknife Radiosurgery to the Kansas City Area and served as Medical Director for the Menorah Cyberknife Center for its first 6 years. In addition to treating the entire range of complex spinal disorders, Dr. Rosenberg is actively involved in treating patients with such modalities as neuromodulation, intrathecal pharmacotherapy, peripheral nerve, spinal cord and deep brain stimulation. He is also very active in training other health care providers, curriculum development and lecturing, as well as designing and supervising clinical trials.

Dr. Rosenberg is a member of the American Association of Neurological Surgeons, Congress of Neurological Surgeons, International Neuromodalation Society, North American Neuromodulation Society, AANS/CNS Joint Section on Pain, American Society of Stereotactic and Functional Neurosurgery, Missouri State Medical Society, Metropolitan Medical and the Kansas City Neurology/Neurosurgery Society. He provides editorial support for Neuromodulation, the official journal of the North American Neuromodalation Society and a number of other professional journals.

EDUCATION AND CREDENTIALS

College of Creative Studies, University of California, Santa Barbara, 1982 B.A.

Harvard Medical School, Boston, Massachusetts, 1987 M.D.

Massachusetts General Hospital, Department of Surgery, Internship, Post Graduate Training, 1987-1988

Massachusetts General Hospital, Department of Neurosurgery, Residency Training, Post Graduate Training, 1988-1992

Massachusetts General Hospital, Department of Neurosurgery, Chief Resident, Post Graduate Training, 1993

Assistant in Neurosurgery, Massachusetts General Hospital, Boston, Massachusettsm, 1994

Assistant Professor, Department of Neurosurgery, University of Cincinnati College of Medicine, Cincinnati, Ohio, 1994-1998

Director, Division of Neurotrauma and Critical Care, University of Cincinnati College of Medicine, Cincinnati, Ohio, 1994-1997

Research Director, Center for Computational Neurobiology, University of Cincinnati, Cincinnati, Ohio, 1995-1998

Adjunct Assistant Professor, Department of Aerospace Engineering and Engineering Mechanics, College of Engineering, 1996-1998

Assistant Professor-In-Residence, University of California School of Medicine, San Francisco, Department of Neurological Surgery, 1998-2002

Co-Director, Neurospinal Disorders Program, University of California School of Medicine, San Francisco, Department of Neurological Surgery, 1998-2002

Chairman, Department of Neurology, Neurosurgery and Psychology,   Menorah Medical Center, Overland Park, KS

Medical Director, Menorah Medical Center CyberKnife Center, Menorah Medical Center, Overland Park, KS, 2004

PUBLICATIONS AND PRESENTATIONS

Rosenberg WS, Swearingen B, Poletti CE: Contralateral trigeminal dysesthesias associated with second cervical nerve compression: A case report.  Cephalgia 10 :259-262, 1990

Rosenberg WS, Rosenberg AE, Poletti CE: Cervical disc herniation presenting as a mass lesion posterior to the odontoid process. Report of two cases.  J Neurosurgery 75 : 954-959, 1991

Rosenberg WS, Breakefield XO, DeAntonio C, Isacson O: Authentic and artifactual detection of the E. coli  LacZ  gene product in the rat brain by histochemical methods.  Mol Brain Res 16 :311-315, 1992

Frim DM, Short MP, Rosenberg WS, Simpson J, Breakefield XO, Isacson O: Local protective effects of nerve growth factor-secreting fibroblasts against excitotoxic lesions in the rat striatum.  J Neurosurgery 78 :267-273, 1993

Rosenberg WS, Harsh GR IV: Penetrating Cerebral Trauma, Including Scalp Lacerations, Depressed Fractures, and Missile Wounds. In: Loftus CM (ed.):  Neurosurgical Emergencies , Volume 1, Chapter 4. New York: McGraw-Hill; 1994, pp 59-72

Godley CD, McCabe CJ, Warren RL, Rosenberg WS: Traumatic subarachnoid-pleural fistula: Case report.  J Trauma 38 :808-811, 1995

Rosenberg WS, Harsh GR IV: Penetrating Wounds of the Head. In: Wilkins RH, Rengachary SS (eds.):  Neurosurgery, 2nd Edition , Volume II. New York: McGraw-Hill; 1996, pp 2813-2820

Rosenberg WS, Tew JM Jr.: Tew cranial/spinal retractor.  Neurosurgery 40 :1096-1098, 1997

Hu H, Nayfeh AH, Rosenberg WS: Composite modeling of human cranial bone. In: Mahmood HF, Barbat SD, Baccouche MR (eds.):  Crashworthiness, Occupant Protection and Biomechanics in Transportation Systems , AMD-Vol. 225/BED-Vol. 38. New York: ASME; 1997, pp 221-32

Roberson JB, Rosenberg WS: Traumatic cranial defects reconstructed with the HTR-PMI cranioplastic implant.  J Cranio-Maxillofacial Trauma 3 :8-13, 1997

Rosenberg WS, Salame KS, Shumrich KV, Tew JM Jr.: Compression of the upper cervical spinal cord causing symptoms of brainstem compromise. A case report.  Spine 23 :1497-500, 1998

Rosenberg WS, Harsh GR IV: Penetrating Cerebral Trauma. In: Grossman, GR and Loftus CM (eds.):  Principles of Neurosurgery, 2nd Edition , Philadelphia: Lippincott-Raven Publishers, 1999

Nagy PB, Rosenberg WS, Stankovits LM: Non-invasive monitoring of acute intracranial mass lesions using ultrasonic fingerprinting. In:  Nondestructive Characterization of Materials in Aging Systems , Pittsburgh: Materials Research Society, Volume 503, pp. 249-54, 1998

Hu H, Rosenberg WS, Nayfeh AH: Modeling human brain movability effect on brain response during impact. In:Mahmood HF, Barbat SD, Baccouche MR (eds.):  Crashworthiness, Occupant Protection and Biomechanics in Transportation Systems , AMD-Vol. 230/BED-Vol. 41. New York: ASME; 1998, pp 267-80

Zemlan FP, Rosenberg WS, Luebbe PA, Campbell TA, Weiner NE, Cohen JA, Rudick RA, Woo D: Quantification of axonal damage in traumatic brain injury: affinity purification and characterization of cerebrospinal fluid Tau proteins.  J Neurochemistry 72: 741-50, 1999

Mummaneni PV, Rosenberg WS: Spinal Chondrosarcoma Following Adenocarcinoma of the Breast: Case Report.  Surgical Neurology 53: 580-2, 2000

Mummaneni PV, Rosenberg WS, McDermott MW: Mucopolysaccharidoses and Spinal Cord Compression: Case Study and Review of the Literature with Implications of Bone Marrow Transplantation [comment].  Neurosurgery 47: 229, 2000

Rosenberg WS, Mummaneni PV: Transforaminal Lumbar Interbody Fusion: Technique, Complications and Early Results.  Neurosurgery 48: 569-75, 2001

Octavio J, Rosenberg W, Conte JE Jr: Surgical Wound Infection from  Pasturella Multocida  from Pet Dogs.  New Engl J Med 345: 549, 2001

Liebschner MAK, Rosenberg WS, Keaveny TM: Effects of Bone Cement Volume and Distribution After Vertebroplasty.  Spine 26:  1547-54, 2001

Rosenberg WS, Theodosopoulos PV: Spinal Tumors In: Prados M (ed.):  ACS Atlas of Clinical Oncology: Brain Cancer  Hamilton: BC Decker, Inc; 2002, pp 365-74

Mummaneni PV, Haddock SM, Liebschner MAK, Keaveny TM, Rosenberg WS: Biomechanical Evaluation of a Double-Threaded Pedicle Screw in Elderly Vertebrae.  J Spinal Disorders 15: 64-8, 2002

Palm WJ, Rosenberg WS, Keaveny TM: Load Transfer Mechanisms in Cylindrical Interbody Cage Constructs.  Spine 27: 2101-7, 2002

Schmidt MH, Quinones-Hinojosa A, Rosenberg WS: Cervical Myelopathy Associated with Degenerative Spine Disease and OPLL.  Seminars in Neurology 22(2): 143-8, 2002

Zemlan FP, Jauch EC, Mulchahey JJ, Gabbita SP, Rosenberg WS, Speciale SG, Zuccarello M. C-Tau Biomarker of Neuronal Damage in Severe Brain Injured Patients: Association with Elevated Intracranial Pressure and Clinical Outcome.  Brain Res 947: 131-9, 2002

Quinones-Hinojosa A, Sanai N, Fischbein NJ, Rosenberg WS: Extensive Intradural Arachnoid Cyst of the Lumbar Spinal Canal: Case Illustration.  Surgical Neurology 60: 57-9, 2003

Liebschner MA, Kopperdahl DL, Rosenberg WS, Keaveny TM. Finite Element Modeling of the Human Thoracolumbar Spine.  Spine 28: 559-65, 2003

Crawford RP, Rosenberg WS, Keaveny TM: Quantitative Computed Tomography-Based Finite Element Models of the Human Lumbar Vertebral Body: Effect of Element Size on Stiffness, Damage and Fracture Strength Predictions.  J Biomech Engineering 125: 434-8, 2003.

Haddock SM, Yeh OC, Mummaneni PV, Rosenberg WS, Keaveny TM: Similarity in the Fatigue Behavior of Trabecular Bone Across Site and Species.  J Biomechanics 37: 181-7, 2004.

Quinones-Hinojosa A, Jun P, Jacobs R, Rosenberg WS, Weinstein PR: General Principles in the Medical and Surgical Management of Spinal Infections: a Multidisciplinary Approach.  Neurosurg Focus 17: E1-15, 2004.

BOOK REVIEW

Mummaneni PV, Rosenberg WS: Review of  Thorascopic Spine Surgery . Dickman CA, Rosenthal DJ, Perin NI (eds). Thieme/New York: Aminoff MJ (ed.), 1999,  Muscle & Nerve  

Request an Appointment

Please call our Kansas City/Lee’s Summit offices at  816-363-2500  and our Overland Park office at 913-340-7980 to request an appointment.

If you have had any studies, such as MRI scans, CAT scans, arteriograms, electromyograms (EMG), or plain x-rays, please bring them with you to your appointment.

       The Highest Quality  of Neurosurgical Care

Midwest Neurosurgery Associates, P.A. – Research Office 2330 E Meyer Blvd, Ste 411 Kansas City, MO 64132

Midwest Neurosurgery Associates, P.A. – Lee’s Summit 1980 SE Blue Parkway, Ste 2130 Lee’s Summit, MO 64063

Midwest Neurosurgery Associates, P.A. – Overland Park Regional 10550 Quivira Rd, Suite 400 Overland Park, KS 66215

Midwest Neurosurgery Kansas City/Lee’s Summit Phone: (816) 363-2500 Fax: (816) 361-4500

Midwest Neurosurgery Overland Park

Phone: (913) 340-7980 Fax: (913) 340-7981

About Midwest Neurosurgery Associates

What We Treat

Location Information

MWNS EMPLOYEES

BC Transparency in Coverage

All information provided on this website is for information purposes only. Please see a healthcare professional for medical advice. If you are seeking this information in an emergency situation, please call 911 and seek emergency help.

Steven A. Rosenberg, M.D., Ph.D.

Senior investigator.

Surgery Branch

Building 10 - Hatfield CRC, Room 3-3940 Bethesda, MD 20892-1201

240-858-3080

[email protected]

Research Topics

Dr. Rosenberg has pioneered the development of immunotherapy that has resulted in the first effective immunotherapies for selected patients with advanced cancer. His studies of cell transfer immunotherapy have resulted in durable complete remissions in patients with metastatic melanoma. He has also pioneered the development of gene therapy and was the first to successfully insert foreign genes into humans. His recent studies of the adoptive transfer of genetically modified lymphocytes has resulted in the regression of metastatic cancer in patients with melanoma, sarcomas and lymphomas.

Dr. Rosenberg is Chief of the Surgery Branch at the National Cancer Institute in Bethesda, Maryland and a Professor of Surgery at the Uniformed Services University of Health Sciences and at the George Washington University School of Medicine and Health Sciences in Washington, D.C. He is a Professor in the Department of Laboratory Medicine at the Karolinska Institutet in Stockholm, Sweden.

Dr. Rosenberg received his B.A. and M.D. degree at The Johns Hopkins University in Baltimore, Maryland and a Ph.D. in Biophysics at Harvard University. After completing his residency training in surgery in 1974 at the Peter Bent Brigham Hospital in Boston, Massachusetts, Dr. Rosenberg became the Chief of the Surgery Branch at the National Cancer Institute, a position he has held to the present time.

Dr. Rosenberg pioneered the first effective immunotherapies for patients with advanced cancer. His basic and clinical studies of interleukin-2 directly resulted in the approval of this immunotherapy by the US Food and Drug Administration for the treatment of patients with metastatic melanoma and renal cancer, many of whom remain disease-free over 25 years after treatment. His studies of cell transfer immunotherapy using tumor infiltrating lymphocytes (TIL) that resulted in durable complete remissions in patients with metastatic melanoma were the first to directly demonstrate the effective role of T lymphocyte in human cancer immunotherapy and the approach has now been applied to the treatment of patients with metastatic solid cancers. He pioneered the development of gene therapy and was the first to successfully insert foreign genes into humans. He was the first to demonstrate the clinical effectiveness of genetically engineered Chimeric Antigen Receptor (CAR) T-cells to mediate the regression of B-cell malignancies in humans, a treatment now approved by the FDA for widespread use. In recent work Dr. Rosenberg established new approaches for the application of immunotherapy to patients with a variety of common solid epithelial cancers by targeting the unique mutations present in the patient’s cancer.

For these contributions Dr. Rosenberg has received the highest awards from virtually every major organization involved in the study of cancer. Recently he received the Keio Medical Science Prize (2012), the American Cancer Society Medal of Honor (2015), the Novartis Prize for Clinical Immunology (2016),the Albany Medical Center Prize (2018), the American Association of Immunology Steinman Award for Human Immunology Research (2019), the Szent-Gyorgi Prize for Progress in Cancer Research (2019), the Edogawa NICHE Prize (2019), the Anthony Cerami Award in Translational Medicine (2019), AACR-CRI Lloyd J. Old Award in Cancer Immunology (2020), Samuel D. Gross Prize from Philadelphia Academy of Surgery (2020), the establishment of the Steven A. Rosenberg Scholars Prize in Cancer Immunotherapy from the Society for Immunotherapy of Cancer (2020), the Dan David Prize in Molecular Medicine from Tel Aviv University, Israel (2021), the Pezcoller Foundation-AACR Award for Extraordinary Achievement in Cancer Research (2022), the 2022 ICON in Surgery Award from the American College of Surgeons, and the Charles M. Balch, MD Distinguished Service Award from the Society of Surgical Oncology (2023), National Medal of Technology and Innovation (2023).

Dr. Rosenberg is a member of the National Academy of Medicine. He has published over 1200 papers in the peer-reviewed literature. His h-index of 208 continues to make him one of the highest cited clinician/scientists in the world.

Selected Publications

• Tran E, Robbins PF, Rosenberg SA. 'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations. Nat Immunol. 2017;18(3):255-262.
• Tran E, Robbins PF, Lu YC, Prickett TD, Gartner JJ, Jia L, Pasetto A, Zheng Z, Ray S, Groh EM, Kriley IR, Rosenberg SA. T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. N Engl J Med. 2016;375(23):2255-2262.
• Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, Wunderlich JR, Somerville RP, Hogan K, Hinrichs CS, Parkhurst MR, Yang JC, Rosenberg SA. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science. 2014;344(6184):641-5.
• Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J, Lin JC, Teer JK, Cliften P, Tycksen E, Samuels Y, Rosenberg SA. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med. 2013;19(6):747-52.
• Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, Morton KE, Laurencot CM, Steinberg SM, White DE, Dudley ME. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011;17(13):4550-7.

Related Scientific Focus Areas

Cancer Biology

View additional Principal Investigators in Cancer Biology

Clinical Research

View additional Principal Investigators in Clinical Research

View additional Principal Investigators in Immunology

This page was last updated on Friday, March 1, 2024

National Cancer Institute - Cancer.gov

Steven A. Rosenberg, M.D., Ph.D.

• Center for Cancer Research
• National Cancer Institute
• Building 10 - Hatfield CRC, Room 3-3940
• Bethesda, MD 20892-1201
• 240-858-3080
• [email protected]

RESEARCH SUMMARY

Dr. Rosenberg has pioneered the development of effective immunotherapies for patients with advanced cancer. His studies of cell transfer immunotherapy using tumor infiltrating lymphocytes (TIL) have resulted in durable complete remissions in patients with advanced solid cancers. He has also pioneered the development of gene therapy and was the first to successfully insert foreign genes into humans. His recent studies of the adoptive transfer of genetically modified lymphocytes using chimeric antigen receptors (CAR) or conventional T-cell receptors (TCR) have resulted in the regression of metastatic cancer in patients with lymphomas and solid cancers. His current research is aimed at defining the host immune response of patients to their cancers. These studies emphasize the ability of human lymphocytes to recognize unique cancer antigens and the identification of anti-tumor T-cell receptors that can be exploited to develop new cell transfer immunotherapies. As Chief, Dr. Rosenberg also oversees the Branch’s extensive clinical program aimed at translating scientific advances into effective immunotherapies for patients with advanced cancers arising from the breast, gastrointestinal tract, and pancreas.

Areas of Expertise

Information for patients.

Learn more about our clinical trials and the highly specialized care teams that lead them. 

Learn more about the Surgery Branch / Cancer Immunotherapy Research Fellowship or submit an application.     

Clinical Trials

Publications, job vacancies.

Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer

Expanded Use for a Single Patient Using Short-Term Cultured, Autologous Tumor-Infiltrating Lymphocytes Following a Lymphodepleting Regimen in a Patient with Metastatic Breast Cancer Plus the Administration of Pembrolizumab

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

Evaluation for NCI Surgery Branch Clinical Research Protocols

Dr. Rosenberg has pioneered the development of immunotherapy that has resulted in the first effective immunotherapies for selected patients with advanced cancer. His studies of cell transfer immunotherapy have resulted in durable complete remissions in patients with metastatic melanoma. He has also pioneered the development of gene therapy and was the first to successfully insert foreign genes into humans. His recent studies of the adoptive transfer of genetically modified lymphocytes has resulted in the regression of metastatic cancer in patients with melanoma, sarcomas and lymphomas.

• View Dr. Rosenberg's PubMed Summary.

Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers

'final common pathway' of human cancer immunotherapy: targeting random somatic mutations, stem-like cd8 t cells mediate response of adoptive cell immunotherapy against human cancer, immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer, t-cell transfer therapy targeting mutant kras in cancer.

Dr. Rosenberg is Chief of the Surgery Branch at the National Cancer Institute in Bethesda, Maryland and a Professor of Surgery at the Uniformed Services University of Health Sciences and at the George Washington University School of Medicine and Health Sciences in Washington, D.C. He is a Professor in the Department of Laboratory Medicine at the Karolinska Institutet in Stockholm, Sweden.

Dr. Rosenberg received his B.A. and M.D. degree at The Johns Hopkins University in Baltimore, Maryland and a Ph.D. in Biophysics at Harvard University.  After completing his residency training in surgery in 1974 at the Peter Bent Brigham Hospital in Boston, Massachusetts, Dr. Rosenberg became the Chief of the Surgery Branch at the National Cancer Institute, a position he has held to the present time.

Dr. Rosenberg pioneered the first effective immunotherapies for patients with advanced cancer. His basic and clinical studies of interleukin-2 directly resulted in the approval of this immunotherapy by the US Food and Drug Administration for the treatment of patients with metastatic melanoma and renal cancer, many of whom remain disease-free over 25 years after treatment. His studies of cell transfer immunotherapy using tumor infiltrating lymphocytes (TIL) that resulted in durable complete remissions in patients with metastatic melanoma were the first to directly demonstrate the effective role of T lymphocyte in human cancer immunotherapy and the approach has now been applied to the treatment of patients with metastatic solid cancers. He pioneered the development of gene therapy and was the first to successfully insert foreign genes into humans. He was the first to demonstrate the clinical effectiveness of genetically engineered Chimeric Antigen Receptor (CAR) T-cells to mediate the regression of B-cell malignancies in humans, a treatment now approved by the FDA for widespread use. In recent work Dr. Rosenberg established new approaches for the application of immunotherapy to patients with a variety of common solid epithelial cancers by targeting the unique mutations present in the patient’s cancer.

For these contributions Dr. Rosenberg has received the highest awards from virtually every major organization involved in the study of cancer. Recently he received the Keio Medical Science Prize (2012), the American Cancer Society Medal of Honor (2015), the Novartis Prize for Clinical Immunology (2016),the Albany Medical Center Prize (2018), the American Association of Immunology Steinman Award for Human Immunology Research (2019), the Szent-Gyorgi Prize for Progress in Cancer Research (2019), the Edogawa NICHE Prize (2019), the Anthony Cerami Award in Translational Medicine (2019), AACR-CRI Lloyd J. Old Award in Cancer Immunology (2020), Samuel D. Gross Prize from Philadelphia Academy of Surgery (2020), the establishment of the Steven A. Rosenberg Scholars Prize in Cancer Immunotherapy from the Society for Immunotherapy of Cancer (2020), the Dan David Prize in Molecular Medicine from Tel Aviv University, Israel (2021), the Pezcoller Foundation-AACR Award for Extraordinary Achievement in Cancer Research (2022), the 2022 ICON in Surgery Award from the American College of Surgeons, and the Charles M. Balch, MD Distinguished Service Award from the Society of Surgical Oncology (2023), National Medal of Technology and Innovation (2023).

Dr. Rosenberg is a member of the National Academy of Medicine. He has published over 1200 papers in the peer-reviewed literature. His h-index of 208 continues to make him one of the highest cited clinician/scientists in the world.

We have no open positions in our group at this time, please check back later.

To see all available positions at CCR, take a look at our Careers page . You can also subscribe to receive CCR's latest job and training opportunities in your inbox.

Steven Rosenberg receives the National Medal of Technology and Innovation

Steven Rosenberg receives AACR Award for Lifetime Achievement in Cancer Research

Landmarks: Development of Cancer Immunotherapy

Landmarks: Cytokines as Therapy

Milestones 2023: Narrowing the Search

Immune receptors recognizing mutations in p53 could guide immunotherapies for solid tumors

Unique gene expression profiles identify rare T cells that could be effective in cancer immunotherapy

NCI study advances personalized immunotherapy for metastatic breast cancer

Milestones 2019: Immunotherapy vs. Breast Cancer

• U.S. Department of Health & Human Services

• Virtual Tour
• Staff Directory
• En Español

You are here

News releases.

Media Advisory

Tuesday, October 24, 2023

NIH immunotherapy pioneer Steven Rosenberg awarded nation’s highest honor for technology and innovation

Immunotherapy pioneer Steven A. Rosenberg, M.D., Ph.D., has been awarded the National Medal of Technology and Innovation by President Biden. It is the nation's highest honor for technological achievement. Dr. Rosenberg is chief of the Surgery Branch at the Center for Cancer Research at the National Cancer Institute, part of the National Institutes of Health.

Awarded by the President of the United States, the National Medal of Technology and Innovation recognizes outstanding contributions to America’s economic, environmental, and social well-being. Dr. Rosenberg will receive his medal from President Biden at a White House ceremony on October 24, 2023. The distinguished oncologist is among nine individuals and a team of three receiving the award this year.

Dr. Rosenberg helped pioneer the development of immunotherapy, a form of treatment that helps a person’s own immune system fight cancer. He identified the anti-cancer properties of a hormone, interleukin-2, that became the first cancer immunotherapy approved by the U.S. Food and Drug Administration.

He was the first to identify immune cells with cancer-fighting properties, called tumor-infiltrating lymphocytes, or TILs. He developed a form of treatment known as adoptive cell transfer (ACT) immunotherapy, in which TILs are extracted from a tumor, grown to large numbers in the lab, and then administered back to a patient as a “living drug” to shrink their tumors. ACT is now being developed by hundreds of academic and industrial centers to treat people with cancer.

Dr. Rosenberg was the first to introduce foreign genes into patients, a development that opened the field of human gene therapy, now being widely studied for many diseases. He was the first to use genetically engineered immune cells, known as CAR T cells, to treat patients with aggressive lymphomas.

In recent work, a clinical trial that Dr. Rosenberg is leading on the use of TILs to selectively target cancer cells led to complete and partial shrinkage of tumors in women with metastatic breast cancer. He is also using TILs to develop personalized cancer immunotherapies for patients whose cancers do not respond to standard treatments.

Steven A. Rosenberg, M.D., Ph.D., Center for Cancer Research, National Cancer Institute

Email [email protected] to schedule an interview with Dr. Rosenberg.

About the National Cancer Institute (NCI): NCI leads the National Cancer Program and NIH’s efforts to dramatically reduce the prevalence of cancer and improve the lives of people with cancer. NCI supports a wide range of cancer research and training extramurally through grants and contracts. NCI’s intramural research program conducts innovative, transdisciplinary basic, translational, clinical, and epidemiological research on the causes of cancer, avenues for prevention, risk prediction, early detection, and treatment, including research at the NIH Clinical Center—the world’s largest research hospital. Learn more about the intramural research done in NCI’s Center for Cancer Research . For more information about cancer, please visit the NCI website at cancer.gov or call NCI’s contact center at 1-800-4-CANCER (1-800-422-6237).

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov .

NIH…Turning Discovery Into Health ®

Connect with Us

• More Social Media from NIH

• WMCHealth Corporate Site
• Westchester Medical Center
• Maria Fareri Children's Hospital
• Behavioral Health Center
• Bon Secours Community Hospital
• Good Samaritan Hospital
• HealthAlliance
• Margaretville Hospital
• MidHudson Regional Hospital
• St. Anthony Community Hospital
• Advanced Physician Services
• Bon Secours Medical Group
• Audio Archive
• COVID-19 Information
• Mountainside Residential Care Center
• Schervier Pavilion
• Sexual Assault and Victim Empowerment
• Find a Provider
• Computed Tomography (CT)
• Digital X-Ray
• Image Management
• Lung Cancer Screening
• MRI (Cardiac)
• Musculoskeletal Imaging
• Neuroradiology Imaging
• Nuclear Medicine
• Pediatric Radiology
• PET/CT Center
• Vascular and Interventional Radiology
• Women's Imaging Center
• Pain Management
• Radiology Residency Program
• Make an Appointment
• Advanced Minimally Invasive Gynecologic Surgery and Pelvic Pain
• Center for Women’s Health Equity
• General Obstetrics and Gynecology
• Ovarian, Fallopian, and Primary Peritoneal
• Endometrial (Uterine Cancer)
• Cervical Cancer
• Vaginal and Vulvar Cancer
• Maternal-Fetal Medicine (Perinatology)
• Reproductive Genetics
• Urogynecology, Female Pelvic Medicine and Reconstructive Surgery
• Anesthesiology Residency Program
• Bariatric and Minimally Invasive Surgery
• Bone Marrow Transplant
• Neurocritical Care Fellowship
• Spine Care Program
• Peripheral Nerve Program
• Neurosurgical Oncology and Skull Base Surgery
• Stroke Care
• Pediatric Neurosurgery
• Pediatric Epilepsy Surgery Program
• Functional Neurosurgery and Adult Epilepsy Surgery Program
• Neurosurgery Residency Program
• CNS Endovascular Fellowship
• Contact Brain and Spine Institute
• Breast Surgery
• Burn Center
• Aortic Aneurysm Surgery
• Coronary Bypass Surgery
• Heart Transplant and Heart Failure
• Hypertrophic Cardiomyopathy Program (HCM)
• Mechanical Circulatory Support | Ventricular Assist Device (VAD)
• Pediatric Cardiothoracic Surgery
• Thoracic Surgery
• Transcatheter Valve Program
• Valve Surgery
• Patient Stories
• Cochlear Connections Newsletter
• Our Research
• Colorectal Surgery
• Care for Families and Patients
• Westchester Medical Center COVID-19 Testing
• WMCHealth Post-COVID-19 Recovery Program
• Department of Medicine
• Dermatology
• Download a Referral Form
• Balance Issues
• Balance Testing and Therapy
• Balance Testing and Therapy: Vestibular and Balance Therapy
• Balance Testing and Therapy: Videonystagmography
• Cochlear Implant Center
• Ear Conditions and Diagnoses
• Ear Surgeries and Procedures
• Ear, Nose and Throat (ENT) Care for Children
• Hearing Loss Conditions and Diagnoses
• Hearing Solutions and Treatments
• Mouth Conditions and Diagnoses
• Nasal Conditions and Diagnoses
• Nasal Surgeries and Procedures
• Neck Conditions and Diagnoses
• Neck Surgeries and Procedures
• Skull Base Surgery
• Skull Base Tumors
• Throat Conditions and Diagnoses
• Throat Surgeries and Procedures
• Voice and Swallowing Program
• e-Health Program
• Emergency Medicine
• Endocrinology and Metabolism
• Flu Vaccine and COVID-19 Booster Shots
• Flu Vaccine Appointments and Screening
• Forensic Acute Care Team (FACT)
• Gastroenterology
• General Surgery
• Gynecologic Oncology
• What-to-Expect
• Headache Procedures
• Headaches and Chronic Pain
• Headache Surgery
• Headache Forms
• Angiograms and Catheterizations
• Angioplasty, Stenting, Atherectomy
• Atrial Septal Defects & PFO
• Balloon Valvuloplasty
• Cardiac Catheterization and Invasive Cardiology
• Cardiac CT Scan
• Cardiac Electrophysiology
• Cardiac Genetic Testing
• About the Director
• Cardiopulmonary Exercise Testing (CPEX)
• Cartoid and Peripheral Arterial Disease
• Catheter Ablation for Cardiac Arrhythmias
• Congenital Heart Disease
• How an Echocardiogram is Performed
• Electrocardiography
• Fractional Flow Reserve
• Medical Management
• Rhythm Management
• Heart Transplant Program
• Holter Monitoring
• Mechanical Circulatory Support
• Nuclear Imaging (Cardiac SPECT, MUGA)
• Pulmonary Hypertension
• Radiofrequency Ablation
• Stress Testing
• Tilt Testing
• Ventricular Assist Devices
• Cardiothoracic Surgery
• Same-Day Cardiology Program
• Vascular Surgery
• Hyperbaric Medicine
• Infectious Diseases
• Integrated Wound Care
• Internal Medicine
• Laboratory Services
• Monkeypox Vaccine
• Memory Disorders Program
• Neurosurgery
• Occupational Health Center
• Ophthalmology
• Musculoskeletal Oncology
• Sports Medicine
• Pediatric Orthopaedics
• Spine and Scoliosis
• Joint Replacement Surgery
• The Ally Care Center
• Palliative Care
• Pediatric Hematology/Oncology
• Advanced Imaging Center
• Advanced OB-GYN Associates
• Brain and Spine Institute | Department of Neurosurgery
• COVID-19: Vaccination, Testing and Treatment
• Ear, Nose and Throat (ENT) / Otolaryngology
• Heart and Vascular Institute
• Orthopaedics / Orthopaedic Surgery
• Pediatric Services
• Psychiatry / Mental Health
• Transplant Center
• Trauma Center
• Vein Center
• Westchester Medical Center Cancer Center
• View All Services
• Pediatric Surgery
• PET / CT Center
• Plastic Surgery
• Preventive Health Screenings, Tests and Immunizations
• Children and Adolescent Psychiatry
• Consultation Liaison
• Interventional Pulmonology
• Rehabilitation Medicine
• Rheumatology
• Surgical Oncology
• Sleep Medicine
• Heart Transplant
• Kidney Transplant
• Liver Transplant
• Pediatric Liver Transplant
• National Donate Life Month
• Varicose Vein Treatment
• Breast Cancer Program
• Cardio-Oncology Program
• Cellular Therapy and Stem Cell Transplantation
• Colorectal Oncology Program
• Genitourinary Oncology
• Hematologic Malignancies (Blood Cancers)
• Pediatric Oncology
• Thoracic Oncology
• Advanced Imaging
• Interventional Oncology
• Radiation Medicine
• Public Reports
• Adolescent and Young Adult (AYA) Program
• WMCHealth COVID-19 Specimen Collection for Testing
• Coronavirus: Need to Know
• WMCHealth Vaccine Information
• Women's Health
• Worksite Wellness Program
• Angiograms & Catheterizations
• Cardiac Catherterization & Invasive Cardiology
• Echocardiography
• Heart Failure
• Abdominal Aortic Aneurysm
• Aortoiliac Occlusive Disease
• Carotid Artery Disease
• Chronic Venous Disease
• Deep Vein Thrombosis (DVT)
• Diabetic Vascular Disease
• Hyperlipidemia
• Hypertension
• Peripheral Artery Disease
• Peripheral Vascular Disease
• Portal Hypertension
• Pulmonary Embolism
• Renal Failure
• Renovascular Conditions
• Thoracic Aneurysm
• Thoracic Outlet Syndrome
• Vascular Malformations
• Arteriogram
• Duplex Ultrasound
• Extremity Blood Pressure
• Magnetic Resonance Angiography
• Magnetic Resonance Imaging
• Plethysmography
• Pulse Volume Recording
• Transcranial Doppler
• Transcutaneous Oximetry
• Caregiver Center
• Clinical Research Programs
• Grateful Patients
• Guides for Patients and Families
• Insurance and Billing
• Medical Records
• Patient Experience
• Patient Information
• Patient Portal
• Patient Rights
• Pre-Procedure Information
• Spiritual Health Services
• Other Resources
• Care Champions
• DAISY Award
• Online Gift Shop
• Patient Family Advisory Councils
• Send an E-Greeting Card
• Upcoming Events
• Visiting Hours and Guidelines
• Refer/Transfer a Patient
• Clinical Trials
• Faculty Development
• Graduate Medical Education
• PGY1 Pharmacy Residency Program
• Foundations of WMCHealth
• Frequently Asked Questions
• Contact Information
• Volunteer Application

Refine Results

Rosenberg, jon b., md.

Specialties

Jon Rosenberg, MD, is an Assistant Professor of Neurology and Neurosurgery and Neurointensivist at Westchester Medical Center. 

Dr. Rosenberg received his medical degree from Albert Einstein College of Medicine, after which he did his internship at Montefiore Medical Center and his neurology residency at the Hospital of the University of Pennsylvania. Following his residency, he completed subspecialty training in Neurocritical Care at New York Presbyterian Columbia College of Physicians & Surgeons and Weill Cornell Medical Center. Dr. Rosenberg is board certified in Neurology and Neurocritical Care by the American Board of Neurology and Psychiatry.

Dr. Rosenberg was drawn to critical care by the breadth of exposure and inherent complexity in managing critically ill patients. As an intensivist, Dr. Rosenberg often sees patients at their worst and most vulnerable. He prides himself on providing comprehensive and thorough care to his patients while supporting their families. He believes that when patients enter the intensive care unit, a partnership forms between the patient's family and the treating team, both of whom must work together to support the patient.

Dr. Rosenberg is also fluent in Spanish. His research interests include developing pathways to advance the delivery of critical care, in addition to examining novel treatment strategies to improve clinical outcomes. He has authored multiple peer-reviewed articles, book chapters, and audio lectures on neurology, stroke, and neurocritical care, and is an active member of the Neurocritical Care Society.

• Psychiatry & Neurology, Neurology

Neurology Associates of Westchester, PLLC

Select "Patients / Caregivers / Public" or "Researchers / Professionals" to filter your results. To further refine your search, toggle appropriate sections on or off.

Home > About the AACR > Newsroom > News Release > Steven A. Rosenberg, MD, PhD, FAACR, Honored with 2024 AACR Award for Lifetime Achievement in Cancer Research

• News Releases
• Media Advisories
• Media Contacts
• AACR Fast Facts
• Apply for Embargoed Access
• Media Coverage
• AACR Cancer Progress Report 2023
• AACR Annual Meeting 2023
• AACR Cancer Disparities Progress Report 2022
• AACR Report on COVID-19 and Cancer 2022
• The AACR June L. Biedler Prize for Cancer Journalism
• San Antonio Breast Cancer Symposium 2023
• Press and PIO Registration
• Embargo Policy
• Media Resources for the AACR Annual Meeting 2024
• Press Program 2023
• Peer-reviewed Journals
• National Cancer Research Month
• Resources for Cancer Center PIOs and Communications Staff
• AACR Stories Index
• AACR Blog: Cancer Research Catalyst
• Cancer Today Magazine

Steven A. Rosenberg, MD, PhD, FAACR, Honored with 2024 AACR Award for Lifetime Achievement in Cancer Research

PHILADELPHIA – The American Association for Cancer Research (AACR) will award Steven A. Rosenberg, MD, PhD, Fellow of the AACR Academy, with the 2024 AACR Award for Lifetime Achievement in Cancer Research during the AACR Annual Meeting 2024 to be held April 5-10 at the San Diego Convention Center in San Diego, California.

Rosenberg is a senior investigator in the Center for Cancer Research at the National Cancer Institute (NCI); chief of the NCI Surgery Branch; head of the Tumor Immunology Section; and professor of surgery at the Uniformed Services University of Health Sciences and at the George Washington University School of Medicine and Health Sciences. He is being honored for his lifelong scientific achievements and paramount contributions to cancer research and patient care, most notably his pioneering research that established interleukin-2 (IL-2) as the first U.S. Food and Drug Administration (FDA)-approved cancer immunotherapy and his major contributions to establishing fundamental principles involving cellular and genetic engineering and immunotherapeutic development.

Through a series of elegant studies, Rosenberg demonstrated that IL-2 has the ability to function as a growth factor for cytotoxic T cells and that treatment with high doses of IL-2 is sufficient to stimulate prolonged tumor regression. These groundbreaking studies would, in turn, lead to the approval of IL-2 as a viable treatment option for metastatic renal cell carcinoma and metastatic melanoma patients.

Following his initial IL-2 studies, Rosenberg continued to pursue the establishment of additional cancer immunotherapies and discovered that IL-2 could be further harnessed as an anti-tumor therapy by stimulating the production of tumor-infiltrating lymphocytes (TILs) in the context of melanoma. He expertly demonstrated that TILs isolated from a melanoma patient could be expanded ex vivo through IL-2 stimulation and subsequently reintroduced into the patient to induce extended durations of tumor regression. This finding helped create the field of adoptive immunotherapy and later resulted in the development of similar cell transfer treatment options for a variety of other cancers, including breast cancer, colorectal cancer, and hepatocellular carcinoma.

This technique also helped establish chimeric antigen receptor (CAR) T cells as effective cellular immunotherapies for the treatment of cancer, namely, hematologic malignancies. Rosenberg and colleagues discovered that T cells may be genetically modified to express various proteins such as CARs. Furthermore, he found that such modified T cells may be designed to recognize target molecules that are specifically expressed by cancer cells, such as the B-lymphocyte antigen CD19. This finding would result in the determination that such CAR T cells represent ideal and effective precision medicine options for the treatment of cancers, such as treatment refractory CD19-positive B-cell lymphoma. CAR T-cell technology has continued to be developed by Rosenberg and others and is currently FDA approved for the treatment of acute lymphocytic leukemia, B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and multiple myeloma, while also being improved and adapted for various other cancer types.

“Dr. Rosenberg’s innovative, groundbreaking research has revolutionized the scientific understanding of the immune response to cancer and resulted in the development of cancer immunotherapies and gene therapies that are saving countless lives around the world,” said Margaret Foti, PhD, MD (hc), chief executive officer of the AACR. “Moreover, he has helped secure the future of the cancer immunotherapy field through his dedication to mentorship and his support of the next generation of cancer researchers. We are very grateful for Dr. Rosenberg’s contributions and thrilled to celebrate his highly productive and impactful career with this prestigious award.”

The  AACR Award for Lifetime Achievement in Cancer Research  was established to honor an individual who has made significant fundamental contributions to cancer research, either through a single scientific discovery or a body of work. These contributions, whether in research, leadership, or mentorship, must have had a lasting impact on the cancer field and must have demonstrated a lifetime commitment to progress against cancer.

Rosenberg has been an AACR member since 1971 and was elected as a Fellow of the AACR Academy in 2015. He received the Pezcoller Foundation-AACR International Award for Extraordinary Achievement in Cancer Research in 2022 and the AACR-Cancer Research Institute Lloyd J. Old Award in Cancer Immunology in 2020.

Throughout his career, Rosenberg has been recognized with a multitude of scientific honors, including the American College of Surgeons Icons in Surgery Award (2022), Health and Human Services Secretary’s Award for Distinguished Service (2021), Dan David Prize, “Future” category (2021), Szent-Györgyi Prize for Progress in Cancer Research (2019), American Association of Immunologists-Steinman Award for Human Immunology Research (2019), Anthony Cerami Award in Translational Medicine (2019), Edogawa NICHE Prize (2019), Helis Prize in Cancer Research (2019), Nathan Davis Award for Outstanding Government Service (2019), Albany Medical Center Prize in Medicine and Biomedical Research (2018), Excellence in Technology Transfer Award (2018), Jacobson Innovation Award (2018), NCI Director’s Award for Translational Science (2018), Federal Technology Transfer Award (2018), James Ewing Award (2016), Novartis Prize for Clinical Immunology (2016), American Cancer Society Medal of Honor (2015), Betty Ford Lifetime Achievement Award of Distinction (2015), Samuel J. Heyman Service to America Medals – Federal Employee of the Year, Partnership for Public Service (2015), Keio Medical Science Prize (2012), William B. Coley Award for Distinguished Research in Basic and Tumor Immunology (2011), Medallion for Scientific Achievement (2006), Richard V. Smalley, MD, Memorial Award (2005), Lila Gruber Memorial Cancer Research Award (2005), American-Italian Cancer Foundation Prize for Scientific Excellence in Medicine (2003), Flance-Karl Award (2002), John Wayne Award for Clinical Research (1996), Claude Jacquillat Award for Achievement in Clinical Oncology (1993), American Society of Clinical Oncology’s David A. Karnofsky Memorial Award and Lecture (1991), and Léopold Griffuel Prize (1988). In 2021, he was elected as a fellow of the Society for Immunotherapy of Cancer (SITC) Academy of Immuno-Oncology.

Rosenberg earned his undergraduate and medical degrees from Johns Hopkins University. He earned a doctorate in biophysics from Harvard University. Rosenberg completed his surgical residency at Peter Bent Brigham Hospital (now Brigham and Women’s Hospital) while simultaneously completing his research fellowship in immunology with John David, MD. Over the course of his illustrious career, he has authored or co-authored more than 30 books and more than 1,000 peer-reviewed publications.

Rosenberg’s award lecture will be presented on Saturday, April 6, at 3 p.m. PT.

• Various Types of Cancer
• Research Funding, Prestigious Research Grants
• Healthcare Professionals Membership

Extraordinary Patients Inspired Father of Cancer Immunotherapy

Widely considered the father of cancer immunotherapy, Steven A. Rosenberg MD, PhD, FAACR, has spent nearly 50 years analyzing the link between patients’ immune reaction and their cancer response.

His pioneering research established interleukin-2 (IL-2) as the first U.S. Food and Drug Administration–approved cancer immunotherapy in 1992.

To recognize his trailblazing work and other achievements, the American Association for Cancer Research (AACR) will award Dr. Rosenberg with the 2024 AACR Award for Lifetime Achievement in Cancer Research at its annual meeting in April.

Dr. Steven A. Rosenberg

Dr. Rosenberg, a senior investigator for the Center for Cancer Research at the National Cancer Institute (NCI), and chief of the NCI Surgery Branch, shared the history behind his novel research and the patient stories that inspired his discoveries, during an interview.

Tell us a little about yourself and where you grew up.

Dr. Rosenberg: I grew up in the Bronx. My parents both immigrated to the United States from Poland as teenagers.

As a young boy, did you always want to become a doctor?

Dr. Rosenberg: I think some defining moments on why I decided to go into medicine occurred when I was 6 or 7 years old. The second world war was over, and many of the horrors of the Holocaust became apparent to me. I was brought up as an Orthodox Jew. My parents were quite religious, and I remember postcards coming in one after another about relatives that had died in the death camps. That had a profound influence on me.

How did that experience impact your aspirations?

Dr. Rosenberg: It was an example to me of how evil certain people and groups can be toward one another. I decided at that point, that I wanted to do something good for people, and medicine seemed the most likely way to do that. But also, I was developing a broad scientific interest. I ended up at the Bronx High School of Science and knew that I not only wanted to practice the medicine of today, but I wanted to play a role in helping develop the medicine.

What led to your interest in cancer treatment?

Dr. Rosenberg: Well, as a medical student and resident, it became clear that the field of cancer needed major improvement. We had three major ways to treat cancer: surgery, radiation therapy, and chemotherapy. That could cure about half of the people [who] had cancer. But despite the best application of those three specialties, there were over 600,000 deaths from cancer each year in the United States alone. It was clear to me that new approaches were needed, and I became very interested in taking advantage of the body’s immune system as a source of information to try to make progress.

Were there patients who inspired your research?

Dr. Rosenberg: There were two patients that I saw early in my career that impressed me a great deal. One was a patient that I saw when working in the emergency ward as a resident. A patient came in with right upper quadrant pain that looked like a gallbladder attack. That’s what it was. But when I went through his chart, I saw that he had been at that hospital 12 years earlier with a metastatic gastric cancer. The surgeons had operated. They saw tumor had spread to the liver and could not be removed. They closed the belly, not expecting him to survive. Yet he kept showing up for follow-up visits. Here he was 12 years later. When I helped operate to take out his gallbladder, there was no evidence of any cancer. The cancer had disappeared in the absence of any external treatment. One of the rarest events in medicine, the spontaneous regression of a cancer. Somehow his body had learned how to destroy the tumor.

Was the second patient’s case as impressive?

Dr. Rosenberg: This patient had received a kidney transplant from a gentleman who died in an auto accident. [The donor’s] kidney contained a cancer deposit, a kidney cancer, unbeknownst to the transplant surgeons. [When the kidney was transplanted], the recipient developed widespread metastatic kidney cancer. [The recipient] was on immunosuppressive drugs, and so the drugs had to be stopped. [When the immunosuppressive drugs were stopped], the patient’s body rejected the kidney and his cancer disappeared. That showed me that, in fact, if you could stimulate a strong enough immune reaction, in this case, an [allogeneic] reaction, against foreign tissues from a different individual, that you could make large vascularized, invasive cancers disappear based on immune reactivities. Those were clues that led me toward studying the immune system’s impact on cancer.

From there, how did your work evolve?

Dr. Rosenberg: As chief of the surgery branch at NIH, I began doing research. It was very difficult to manipulate immune cells in the laboratory. They wouldn’t stay alive. But I tried to study immune reactions in patients with cancer to see if there was such a thing as an immune reaction against the cancer. There was no such thing known at the time. There were no cancer antigens and no known immune reactions against the disease in the human.

Around this time, investigators were publishing studies about interleukin-2 (IL-2), or white blood cells known as leukocytes. How did interleukin-2 further your research?

Dr. Rosenberg: The advent of interleukin-2 enabled scientists to grow lymphocytes outside the body. [This] enabled us to grow t-lymphocytes, which are some of the major warriors of the immune system against foreign tissue. After [studying] 66 patients in which we studied interleukin-2 and cells that would develop from it, we finally saw a disappearance of melanoma in a patient that received interleukin-2. And we went on to treat hundreds of patients with that hormone, interleukin-2. In fact, interleukin-2 became the first immunotherapy ever approved by the Food and Drug Administration for the treatment of cancer in humans.

Recommended Reading

• Immunotherapy
• Practice Management
• Mixed Topics
• Metastatic Breast Cancer
• Sarcoma & GIST
• Renal Cell Carcinoma
• Patient & Survivor Care
• Nonmelanoma Skin Cancer
• Lymphoma & Plasma Cell Disorders
• Lung Cancer
• Leukemia, Myelodysplasia, Transplantation
• Immuno-oncology
• Gynecologic Cancer
• Head & Neck/Thyroid Cancers
• Genitourinary Cancer
• Gastrointestinal Cancer
• Follicular Lymphoma
• Breast Cancer
• CNS/Brain Cancer
• Aggressive Lymphomas
• B Cell Lymphoma
• Business of Medicine
• Hodgkin Lymphoma
• Indolent Lymphoma
• Mantle Cell Lymphoma
• Multiple Myeloma
• Non-Hodgkin Lymphoma
• T Cell Lymphomas
• Neuro-oncology
• MDedge Home
• Clinician Reviews
• Dermatology
• Emergency Medicine
• Endocrinology/Diabetes
• Family Medicine
• Federal Practitioner
• Gastroenterology
• Hematology/Oncology
• Infectious Disease
• Internal Medicine
• Obstetrics And Gynecology
• Pulmonology
• Rheumatology

Your cart is empty

Have an account.

Log in to check out faster.

Item added to your cart

It started with a simple mission:

Create the world’s best supplements.

To do that, we knew we needed…

Dr. Mark Rosenberg

The “Doctor’s Doctor”

Mark Rosenberg doesn’t write books or make regular appearances on TV shows. That’s because he’s committed to serving his patients, advancing new research, writing research papers, and lecturing to other physicians.

His medical career is second-to-none: It started with a medical degree from the Georgetown School of Medicine. He went on to win the Teacher and Resident of the Year Award, at the Brooke Army Medical Center. Then he served in the ER at the Beth Army Medical Center, and eventually, came to manage the ER at the Walter Reed Army Medical Center.

But everything changed, the day that his own mother showed up in his ER, complaining of tightness in her chest. 45 minutes later, Dr. Rosenberg was the one to diagnose her with advanced-stage lung cancer. He soon quit the ER, and threw himself into research on cancer therapies, and longevity treatments.

Dr. Rosenberg wasn’t able to save his mother, but many years later, his research saved the lives of two Stage-4 patients, who are still in remission to this day. That treatment is now in pre-clinical trials.

In the medical community, Dr. Rosenberg is widely known and respected. He’s the doctor who other doctors come to see for preventative care. He now regularly lectures to tens of thousands of other physicians, and serves on the board of the American Academy of Anti-Aging Medicine. He also operates the Advanced Medical Therapies clinic, in Boca Raton, where his patients receive bespoke medical care, with a proactive approach.

With Help From Dr. Steve Sisskind

Dr. Steve Sisskind is both an accomplished M.D., and a successful businessman. Long an advocate of preventative care, it was an illness in his own family which led him to discover the importance of supplements.

Dr. Sisskind serves as the Chief Operating Officer at Sun Coast Sciences, where he works closely with Dr. Rosenberg on research, and personally manages our supply chain and manufacturing.

Proactive Health

Dr. Rosenberg has been outspoken about his disappointment with the health and medical establishment:

“In my two decades operating in an ER, I became a firm believer in the power of Western Medicine, especially for acute injuries and emergencies. But the food-health-industrial complex is very good at making us sick, and profiting off our illness… and I saw far too many patients who could have avoided a visit if they’d had better guidance and treatment in the years prior. So when I transitioned into research, my goal was to reduce the number of people who ever had to visit an ER in the first place. And that meant targeting the root cause of their health issues.”

For Dr. Rosenberg, that means a comprehensive, proactive approach to wellness, in every system in their body: from digestion, to immunity, to endocrine and more. He works closely with patients to make sure they’re one step ahead. And now, as Chief Medical Advisor to Sun Coast Sciences, he’s taking this proactive care to more Americans.

Introducing Sun Coast Sciences

What does it mean to create the world’s best supplements? It begins with another question: what’s the desired outcome for this supplement? A great night’s sleep? A healthy immune system? Peak brain function?

Once that’s decided, we work with Dr. Rosenberg to create a formula where “the whole is greater than the sum of its parts.” We review extensive clinic studies to find the right ingredients, at the right serving sizes, to get the intended outcome. We select premium, highly bioavailable versions of our ingredients. And we test our formulas internally, before they’re ever released to the world.

Every product we create has to have see-it, feel-it results. That’s how we know that our supplements are the best in the world, and it’s why our customers become loyal for life.

We skip retail, and sell direct to customers and clinics. That’s how we ensure the purity, and freshness, of every order.

It’s Time To Try The Best Supplements In The World

No matter what aspect of your health you’re looking to support, Sun Coast Sciences has a formula for you. You’ll see the results, and you’ll feel them - that’s our promise. Every order comes with a one-year guarantee, so head over to our store right now, and let us become a trusted partner in your path to peak health.

• Choosing a selection results in a full page refresh.

Dr. Mark A. Rosenberg

Book an appointment at Advanced Medical Therapeutics

with Dr. Mark A. Rosenberg

About Dr. Mark A. Rosenberg

Dr. Mark Rosenberg MD is a medical doctor and researcher specializing in healthy aging and integrative cancer therapy . He founded and leads the AMT’s Institute for Healthy Aging and Integrative Cancer Therapeutics , which merges traditional western medicine with complementary and alternative medicine to optimize patients’ health.

Dr. Mark A. Rosenberg's Credentials

Education & certificates.

• Bachelor of Arts in Biology from the University of Pennsylvania (Sept 1978 – May 1982)
• Master of Science in Physiology from Georgetown University Graduate School (July 1982 – June 1983)
• Doctor of Medicine from Georgetown University School of Medicine (July 1984 – May 1988)

Medical Training:

• Transitional Internship at Fitzsimons Army Medical Center, Aurora, CO (July 1988 – July 1989)
• Emergency Medicine Residency at Brooke Army Medical Center Dept. of Emergency Medicine, San Antonio, TX (July 1990 – July 1993)

Certifications:

• Board-Certified by the American Board of Emergency Medicine (1994)
• Fellow of the American College of Emergency Physicians (1996)
• Diplomate of the National Board of Medical Examiners (1989)
• ACLS Provider from American Heart Association (1988-Present)
• PALS Provider from American Academy of Pediatrics (1990-1992)
• ATLS Provider and Instructor from American College of Surgeons (1989-1999)
• Diplomate of the American Academy of Anti-aging Medicine (2001)
• Board Certified from American Academy of Anti-aging Medicine (2009)
• Certified Hypnotherapist from National Guild of Hypnotists (1998)
• Certified Personal Trainer from National Strength and Conditioning Assoc. (1998)

Specialties

Internal Medicine Doctor, Primary Care Doctor, Emergency Medicine Doctor, Integrative Medicine Doctor

Types of Cancer Treatment

• Anal Cancer
• Bladder Cancer
• Bone Cancer
• Brain Cancer
• Breast Cancer in Women
• Cervical Cancer
• Colon Cancer
• Colorectal Cancer
• Esophageal Cancer
• Gastric Cancer
• Hereditary Colorectal Cancer
• Hereditary Nonpolyposis Colorectal Cancer (HNPCC)
• Hereditary Nonpolyposis Colorectal Cancer Syndrome
• Inflammatory Breast Cancer
• Kidney Cancer
• Liver Cancer
• Lung Cancer
• Mouth Cancer
• Nonhereditary Colorectal Cancer
• Non-Melanoma Skin Cancer
• Oral Cavity Cancer
• Ovarian Cancer
• Prostate Cancer
• Recurrent Breast Cancer
• Renal Cancer
• Sporadic Colorectal Cancer
• Stomach Cancer
• Testicular Cancer
• Thyroid Cancer
• Uterine Cancer
• Womb Cancer

Typical Program Length

Dr. Mark Rosenberg MD provides a la carte services at Advanced Medical Therapeutics

Years of Experience

Languages spoken.

English, Spanish

Where Dr. Mark A. Rosenberg practices

Advanced medical therapeutics.

6100 Glades Rd

Videos from YT of Dr. Mark A. Rosenberg

Mod vii - cancer - immune dysregulation and novel treatment approach.

Cancer - Immune Dysregulation and Novel Treatment Approach Mark Rosenberg, MD

Insurances Accepted by Dr. Mark A. Rosenberg

Frequently asked questions about dr. mark a. rosenberg.

Dr. Mark Rosenberg MD specializes in healthy aging and integrative cancer therapy.

Dr. Mark Rosenberg MD has earned a reputation for resolving aging and cancer challenges that traditional medicine has not addressed through the latest medical and nutritional science and innovative therapies.

You can reach out to Dr. Mark Rosenberg MD by clicking the call button above or book now to set an appointment.

Practices At:

Have some feedback for our website? Visit our Contact Us page or shoot us an email at [email protected] !

• Our Company
• Publications
• News & Events
• Research & Development
• Join our PSI team
• Data & Sensor Exploitation
• Microwave Technologies
• PSI Production
• Licensed Tech
• Prototypes & Emerging Tech
• Defense and Security
• Medical and Pharma
• Energy and Environment
• Why Employee Owned Matters
• Greater Boston Area
• Career Paths
• Open Positions
• CBRN Sensors and Systems
• Space and Missile Test Services and Systems
• Pharma and Biomedical Sensors
• High Temperature Composites
• Optical Devices
• Passive Optical Sensors
• LIDARs and Laser Based Sensors
• Sensor Networks
• Missile Test Equipment
• Space Systems
• Materials & Structures
• Propulsion Systems
• Electricity and Magnetism Sources and Systems
• Employee Vignettes
• Job Application Form
• PERL Ecosystem

Static Installations

• Field Services
• HT Test Services
• AO Test Services
• Lyo Proc Dev
• Transpar Prostate
• Hybrid Composite Systems
• Castable, Chopped Fiber Composites
• Pre-preg Braiding of Organic Composites
• Direct Z-pin Insertion
• Flexible Thermal Protection Systems
• Chemical Vapor Deposition
• Meta Materials
• Quantum Sensors
• VNIR/SWIR HSI
• HSI Gimbals
• CS Flash LIDAR
• Handheld K Meter
• Terrain Map
• Plume Imager
• Diamonds Coatings
• Phase Change
• Large Space Structures
• Space Antennas
• SMART Sleeve
• SMART Cell Sorter
• Optical Diag Endo
• Brain Imager
• Nerve Imager
• Optical Redux Probe
• Singlet Oxygen Dosimeter
• Biologics Lyophilization
• Pharmaceutical Lyophilization
• Engines & Solid Motors
• Additively Manufactured Scramjets
• Ultra-Compact Heat Exchanger
• High-Power Microwaves
• Terrestrial Antennas
• Fielded Mechanisms
• Antimicrobials
• Rare Earth Element Recovery
• Rotating Detonation Engines
• Green Monopropellant Thruster
• 2×4 Solid Rocket Motor
• 5” – 8” Solid Rocket Motor Test Cell
• Propulsion And Power Systems
• Aluminum Hydride (Alane)
• ASCENT Monopropellant
• Combustible Cartridge Cases
• Insensitive Munition Compliant Composite Case
• Fine Ammonium Perchlorate

Products > CBRN Sensors and Systems > Mobile Systems

Mobile Systems

A fully supported modular product line that enables CONOPs-optimized configurations while providing actionable information.

For more technical information on CBRN products and the PERL detection ecosystem, contact: Bogdan Cosofret, Vice President, Detection Systems [email protected] Our products are also available for sale on GSA Advantage!

Advanced vehicle-based platforms for real-time detection and identification of cbrn threats in complex and variable urban environments..

MURS 2.0 is an advanced mobile radiation detection, identification and source localization system coupled with day/night contextual imaging and inertial navigation subsystems discreetly installed in a 4x4 vehicle. The MURS assembly was designed to meet the MIL-STD-810G Ground Mobile requirements for shock, vibration and impact. The system offers unparalleled urban threat detection, identification and tracking with actionable information through high resolution contextual imagery and interactive urban maps.

PERM-Mobile™

PERM-Mobile is an advanced, modular sensor platform capable of providing radiation detection, source identification, and contextual information in both mobile and static applications. The platform is easily installed in mid-size SUVs and larger vehicles, while a wide input power range allows the system to operate from universal AC power or the vehicle’s 12V supply (via cigarette lighter plug). An optional compact stanchion, which fits between the PERM-Mobile frame, can be erected in < 10 minutes as a radiation portal monitor for static applications.

PERM-MobileCBRN™

PERM-Mobile CBRN integrates chem/bio detection channels with the R/N capability found in the standard PERM-Mobile package. The integrated chemical sensor is based on a water chemistry configuration of the Bruker RAID-P Ion Mobility Spectrometer interfaced with a processing module that executes PSI’s machine learning (ML)-based detection and identification algorithms to enable significantly improved performance against 10 chemical warfare agents (CWAs) and 20 toxic industrial chemicals and precursors. The bio detection channel uses the Battelle REBS+ Raman-based sensor to achieve detection sensitivity against 84 pathogens.

CBRN Sensor Integration

Mobile RN Sensor Integration

RN Detectors

Data & Sensor Exlploitation

PSI Production CBRN Sensors and Systems

Innovative mounting solutions for maximizing the probability of intercepting R/N sources.

PERL™ Ecosystem

Production, maintenance, training and sustainability.

Flexible production facility with QMS and capable of rapid scaling. A committed team of experienced field service engineers who provide on-site support when needed.

Chem/Bio SIGMA

Trigger Initiated Graph Examiner

Adaptive Infrared Imaging Spectroradiometer

• © 2024 Physical Sciences Inc.
• 20 New England Business Center, Andover, MA 01810
• (978) 689-0003
• [email protected]
• Privacy Policy
• Terms of Use
• Cookies Disclaimer

• New" target="_self" >What's New
• Dr. Mark Rosenberg
• ICT Overview
• Testimonials
• Research Institute
• Diagnostics
• Treatment Days
• Funding Options
• Optimizing my Chances for Successful Cancer Treatment
• Low-Dose Metronomic Chemotherapy
• pH Manipulation Therapy
• IV Therapies
• Diet and Nutrition
• Supplements / Nutraceuticals
• Off Label Use of Pharmaceuticals
• Offshore Clinical Trials
• Intra-tumoral Treatment
• Intravenous Albumin infusions
• Understanding the Differences
• DCA (Dichloroacetate)
• Immunotherapy Using Checkpoint Inhibitors
• Recurrence of Cancer" target="_self" >High Risk for Recurrence of Cancer
• Why Consider Alternatives to Conventional Chemotherapy?
• Cancer Stem Cells
• Research & Clinical Studies

Dr. Mark Rosenberg received his doctorate from Georgetown University School of Medicine in 1988 and has been involved with drug research since 1991. With numerous certifications in several different fields of medicine, psychology and fitness, Dr. Rosenberg has a wide breadth of experience in both the public and private sector with particular expertise in the mechanisms of cancer treatment failure. Dr. Rosenberg is an innovator, constantly developing new ideas, techniques, and drugs, to combat incurable diseases. Many countries outside of the U.S. allow novel drugs that have not gone through FDA trials to be administered to terminally ill patients with no other options. Taking advantage of this option, Dr. Rosenberg intermittently travels outside of the country where he treats individuals who are considered end-stage. Curriculum Vitae for Mark Rosenberg, MD, FACEP

• July 1990 – July 1993 Emergency Medicine Residency Brooke Army Medical Center Dept. of Emergency Medicine San Antonio, TX
• July 1988 – July 1989 Transitional Internship Fitzsimons Army Medical Center Aurora, CO
• July 1984 – May 1988 Doctor of Medicine Georgetown University School of Medicine Washington, DC
• July 1982 – June 1983 Master of Science in Physiology Georgetown University Graduate School Washington, DC
• Sept 1978 – May 1982 Bachelor of Arts in Biology University of Pennsylvania Philadelphia, PA

Committees/Advisory Board

• 2011 - Present; Medical Advisor to Life Length Telomere Analysis Technology
• 2003 - 2005; Chairman of Pharmacy and Therapeutics Committee, Bethesda Memorial Hospital
• 2003 - 2005; Institutional Review Board, Bethesda Memorial Hospital
• 2003 - Present; Consultant to the National Strength and Conditioning Assoc.
• 2000 - 2005; Emergency Department Committee, Bethesda Memorial Hospital
• 1999 - Present; Medical Advisor to Fitness Institute International
• 1990 - Present; American College of Emergency Physicians

Certifications

• 2009; Board Certified, American Academy of Anti-aging Medicine
• 2001; Diplomate of the American Academy of Anti-aging Medicine
• 1996; Fellow of the American College of Emergency Physicians
• 1994; Board-Certified by the American Board of Emergency Medicine
• 1989; Diplomate of the National Board of Medical Examiners
• 1989-1999; ATLS Provider and Instructor, American College of Surgeons
• 1990-1992; PALS Provider, American Academy of Pediatrics
• 1988-Present; ACLS Provider, American Heart Association
• 1998; Certified Hypnotherapist, National Guild of Hypnotists
• 1998; Certified Personal Trainer, National Strength and Conditioning Assoc.
• 1989; US Army Certificate of Achievement Award, for performance above and beyond the call of duty during the tornado disaster in Alabama
• 1989; US Army Commendation Medal
• 1993; Award for Outstanding Senior Resident and Teacher
• 1999; Valedictorian and Distinguished Speaker, Fitness Institute International
• 1999; Cover of the monthly journal, "The Florida Hypnotist"

Publications

• Epstein A, Zhang D, Schultz J, Rosenberg M, Kupcha P, Stellar E: The Failure of Ventricular Sodium to Control Sodium Appetite in the Rat; Journal of Physiology and Behavior. 32:683-686, 1984
• Rosenberg, Mark A: Toxndex, Toxicological Emergency Reference Manual; Delray Beach, FL, MQ INC, 1991

Research Experience

• Patent Pending in the U.S., Canada, and the European Union - CCK based oral appetite suppressant for the treatment of obesity, filed February 23, 2007
• Development of "Cancer Cocktail"; U.S. Application Serial No. 13/464,896 Title: Cytotoxic Therapy By Proton Flux Modulation Date Filed: May 4, 2012
• IND status granted Feb 24, 2007 for use of angiotensin II to improve tumor blood flow during administration of cytotoxic cancer therapy
• 2007- Wake Forest University; Inhibition of tumor growth in mice through glycolytic inhibition
• 2009 - University of Miami; Inhibition of cancer growth (in vitro) through inhibition of proton pump and monocarboxylate transporters

Professional Experience

• 2012 – Present; Medical Director; AML Diagnostics
• 2012 – Present; Board of Directors; American Academy of Anti-aging medicine
• 2011 – Present; Medical Advisor to Life Length Telomere Analysis Technology
• 2010 – 2012; Medical Director, Age Diagnostic Laboratories
• 2009 – Present; Program Director; Integrative Cancer fellowship
• 2008 – Present; Chief Medical Officer; Rose Pharmaceuticals
• 2006 – Present; Chief Science Officer and Director of research and Development; Vitalmax Vitamins
• 2003 – Present; President and Medical Director The Institute for Healthy Aging, Delray Beach, FL
• 2003 – 2004; Chief Science Officer and Director of Research and Development, “Nutrophy”, Miami, FL
• 1999 – 2005; Assistant Director of Emergency Medicine, Bethesda Memorial Hospital, Boynton Beach, FL
• 1996 – 1999; Associate Director of Emergency Medicine and Director of Quality Improvement, Westside Regional Medical Center, Plantation, FL
• 1993 – 1996; Assistant Chief of Emergency Medicine; Consultant for Poisons and Overdoses; Director of Quality Improvement Walter Reed Army Medical Center, Washington, DC
• 1995 – 1996; Staff Emergency Physician, Shady Grove Adventist Hospital, Rockville, MD
• Therapeutics" target="_self" >Integrative Cancer Therapeutics
• Healthy Aging" target="_blank" >Institute For Healthy Aging
• Donation" target="_blank" >Research & Donation
• Integrative Cancer Therapeutics
• Institute For Healthy Aging

Copyright © 2015 Advanced Medical Therapeutics. All Rights Reserved.

Medical Website Design by WebToMed

Login: Residents | Students

• Program Introduction
• Chairman's Welcome
• Director's Welcome
• Associate Director's Welcome
• Programs and Initiatives
• Program Facts
• Program Benefits
• Application Process
• Interview Day Schedule
• Jacobi Medical Center
• Meet The Jacobi Family
• Where Do The Residents Live?
• Resident As Teacher
• About the Bronx
• Research in Progress
• Noon Conferences
• Grand Rounds Schedule
• A Proud History
• Our Mission
• Lewis M. Fraad
• Contact Information
• Public Transportation
• Driving Directions

Award & Honors:

• Henry Barnett Departmental Teaching Award, Lewis M. Fraad Department of Pediatrics, Jacobi Medical Center (2008)

Clinical Focus:

• Opportunistic infections
• Cell mediated immunity in HIV
• New treatments for HIV

Faculty Profile

Michael G. Rosenberg, MD, PhD Phone: 718-918-4677 E-mail: [email protected]

Dr. Rosenberg is an Attending in the Division of Pediatric Infectious Diseases. He is committee member of the New York State HIV Clinical Guidelines Program. Dr. Rosenberg is board certified in Pediatric Infectious Diseases and he is an Associate Professor of Clinical Pediatrics at the Albert Einstein College of Medicine.

Undergraduate School:

Graduate School:

Medical School:

• Internship and Residency: Montefiore Medical Center
• Infectious Disease Fellowship: Montefiore Medical Center

Bibliography:

• Champiat S, Rosenberg MG , Wiznia AA, et al: T cells target APOBEC3 proteins in human immunodeficiency virus type1-infected humans and simian immunodeficiency virus-infected indian rhesus macaques. J Virol 2013 Jun;87(11):6073-80.
• Tandon R, Wiznia AA, Rosenberg MG , et al: Age-related expansion of Tim-3 expressing T cells in vertically HIV-1 infected children. PLoS One 2012;7(9):e45733.
• Sharp ER, Kuebler PJ, Abadi J, Fennelly GJ, Dobroszycki J, Wiznia AA, Rosenberg MG , et al: Nixon DF. Association of differentiation state of CD4+ T cells and disease progression in HIV-1 perinatally infected children. PLoS One 2012;7(1):e29154.
• Nixon DF. Association of differentiation state of CD4+ T cells and disease progression in HIV-1 perinatally infected children. PLoS One 2012;7(1):e29154.
• Tandon R,Wiznia AA, Rosenberg MG , et al: Identification of human endogenous retrovirus-specific T cell responses in vertically HIV-1-infected subjects. J Virol 2011 Nov;85(21):11526-31.
• Sharp ER, Abadi J, Fennelly GJ, Dobroszycki J, Wiznia AA, Rosenberg MG , et al: Immunodominance of HIV-1 specific CD8+ T-cell responses is related to disease progression rate in vertically infected adolescents. PLoS One 2011;6(7):e21135.
• Phillips UK, Rosenberg MG , Dobroszycki Wiznia AA, Abadi J. et al: Pregnancy in women with perinatally acquired HIV-infection: outcomes and challenges. AIDS Care 2011 Sep;23(9):1076-82.
• Holditch SJ, Wiznia AA, Rosenberg MG , et al: Decay kinetics of HIV-1 specific T cell responses in vertically HIV-1 exposed seronegative infants. Front Immunol 2011;2:94.
• Lee AW, Sharp ER, O'Mahony A, Rosenberg MG , Iet al: Single-cell, phosphoepitope-specific analysis demonstrates cell type- and pathway-specific dysregulation of Jak/STAT and MAPK signaling associated with in vivo human immunodeficiency virus type 1 infection. J Virol 2008;82:3702-12.
• Ballan WM, Wiznia AA, Abadi J, Fennelly GJ, Rosenberg MG , et al: Natural killer cells in perinatally HIV-1-infected children exhibit less degranulation compared to HIV-1-exposed uninfected children and their expression of KIR2DL3, NKG2C, and NKp46 correlates with disease severity. J Immunol 2007 Sep 1;179(5):3362-70.
• Ballan WM, Vu BA, Rosenberg MG , et al: Natural killer cells in perinatally HIV-1-infected children exhibit less degranulation compared to HIV-1-exposed uninfected children and their expression of KIR2DL3, NKG2C, and NKp46 correlates with disease severity. J Immunol 2007;179:3362-70.
• Abadi J, Sprecher E, Rosenberg MG , et al: Partial treatment interruption of protease inhibitor-based highly active antiretroviral therapy regimens in HIV-infected children. J Acquir Immune Defic Syndr 2006;41:298-303.
• Jordan KA, Furlan SN, Rosenberg MG , et al: CD8 T cell effector maturation in HIV-1-infected children. Virology 2006;347:117-26.
• Sharp ER, Barbour JD, Rosenberg MG , et al: Higher frequency of HIV-1-specific T cell immune responses in African American children vertically infected with HIV-1. J Infect Dis 2005;192:1772-80.
• Legrand FA, Abadi J, Rosenberg MG , et al: Partial treatment interruption of protease inhibitors augments HIV-specific immune responses in vertically infected pediatric patients. AIDS 2005;19:1575-85.
• Chandwani R, Jordan KA, Rosenberg MG , et al: Limited magnitude and breadth in the HLA-A2-restricted CD8 T-Cell response to Nef in children with vertically acquired HIV-1 infection. Scand J Immunol 2004;59:109-14.
• Rosenberg M : HIV-related emregncies, in Crain EF, Gershel, JC (eds.): Clinical Manual of Emergency Pediatrics (4th ed), McGraw-Hill, New York, 2003, pp 354-60.
• Sullivan PS, Beck DT, Rosenberg M , Dobroszycki J: Depression of blood cells in HIV-infected children and adolescents, in Shearer WT, Hanson IC (eds): Medical Management of AIDS in Children, Saunders/Elsevier, Philadelphia, 2003, pp 321-35.

Lewis M. Fraad Department of Pediatrics Albert Einstein College of Medicine at Yeshiva University 1400 Pelham Parkway South, Bronx, New York 10461 718.918.6981

Residency Program

• Chaiman's Welcome
• Faculty Listing

Research & Publications

• All Publications

News & Events

• Social Events
• Conferences
• Grand Round Schedules

About the Department

• Directions By Public Transportation
• Driving Directions By Google Maps

Yeshiva University | Albert Einstein College of Medicine | Family Advocacy | Pediatrics Emergency Medicine | Jacobi Medical Center